drugset
drugset / Trial / NCT00076206

Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy

NCT00076206 ↗

Phase 2 Terminated Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to compare the therapeutic response and safety of 3 oral dose levels of CCI-779, with placebo in subjects with active rheumatoid arthritis (RA) who have been receiving stable doses of methotrexate (MTX) for at least 8 weeks.

Timeline

Start
2003-12
Primary completion
2005-08
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Temsirolimus Small molecule 1 mg Oral
Subject Temsirolimus Small molecule 2 mg Oral
Subject Temsirolimus Small molecule 4 mg Oral

Indications

rheumatoid arthritis